Gilead small molecule demonstrates strong capability for HIV prevention
According to Gilead, the study is the first Phase III HIV prevention trial to demonstrate a zero-infection rate.
List view / Grid view
According to Gilead, the study is the first Phase III HIV prevention trial to demonstrate a zero-infection rate.
The world‘s first international trial into second-line HIV therapy has shown two simplified treatments are at least as effective as standard of care.
Phase 3 trials of Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability and low resistance